Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next?

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) fell 7.5% on Friday . The company traded as low as $2.46 and last traded at $2.46. 48,743 shares changed hands during mid-day trading, an increase of 18% from the average session volume of 41,268 shares. The stock had previously closed at $2.66.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH raised their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Trading Down 7.5 %

The firm’s fifty day moving average price is $3.38 and its two-hundred day moving average price is $3.66.

Insiders Place Their Bets

In other Marker Therapeutics news, major shareholder Enterprise Associates 16 New bought 554,250 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the transaction, the insider now directly owns 1,625,678 shares in the company, valued at approximately $5,202,169.60. The trade was a 51.73 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Steve Elms bought 11,085 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the acquisition, the director now directly owns 325,370 shares in the company, valued at $1,041,184. The trade was a 3.53 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 17.35% of the company’s stock.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Invst LLC purchased a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned approximately 0.22% of Marker Therapeutics at the end of the most recent quarter. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.